Our mission is to develop compounds in oncology areas of high unmet medical need through collaborations with leading research institutes and biotech's.
Pega-One S.A.S. is a French biotech firm founded in 2020 and acquired by Phoenix Biopharma Co., a US based biotech firm, in 2023.
We are developing Imgatuzumab, a humanized, glycoengineered, anti-EGFR monoclonal antibody (mAb) with enhanced Antibody Derived Cell Cytotoxicity (ADCC) and (Antibody Derived Cell Phagocytosis (ADCP) properties, for the treatment of solid tumors
Copyright © 2023 Pega-One S.A.S - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.